Table 3 Mean (SD) NHS costs in Euros per patient in the pre-intervention and post-intervention period
From: Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study
Pre-intervention period | Post-intervention period | p-value† | |
|---|---|---|---|
Hospitalizations | 124.8 (744.4) | 38.4 (288.8) | 0.153 |
Respiratory | 87.9 (664.1) | 10.4 (137.6) | 0.131 |
Non respiratory | 36.9 (345.9) | 28.0 (255.0) | 0.783 |
Emergency room visits | 24.2 (142.4) | 30.0 (205.9) | 0.758 |
Respiratory | 7.3 (62.9) | 3.8 (40.0) | 0.530 |
Non respiratory | 16.9 (93.3) | 26.3 (168.4) | 0.519 |
Drugs | 337.7 (427.0) | 6394.7 (1673.8) | < 0.001 |
Dupilumab | 0 (0) | 6008.2 (1185.7) | < 0.001 |
Mepolizumab and Benralizumab | 0 (0) | 0 (0) | – |
Specifics* | 199.1 (181.5) | 160.0 (182.6) | 0.045 |
Others | 138.7 (352.5) | 226.4 (1263.1) | 0.376 |
Outpatient services | 212.8 (370.9) | 320.4 (401.5) | 0.009 |
Respiratory | 13.1 (36.9) | 35.6 (79.0) | 0.001 |
Non respiratory | 199.7 (360.6) | 284.9 (384.6) | 0.033 |
Total | 699.5 (1189.4) | 6783.5 (1858.0) | < 0.001 |